

FINANCIAL COMMUNICATION

Paris, April 25, 2022

Generix Group announces the resumption of its listing as of April 26, 2022

Generix Group, Industrial, Logistics and Retail Ecosystems provider with leading Collaborative SaaS Solutions, announces the resumption of its listing as of Tuesday, April 26, 2022.

The Group suspended its listing on Monday April 25, 2022 in the context of the announcement made on the evening of April 22, 2022 concerning the entry into exclusive negotiations between Generix, its management, Pléiade Investissement, and Montefiore Investment, with a view to concluding an investment protocol leading to the filing of a public takeover bid at a price of €9.50 per share, with an incentive of €0.50 per share if the 90% delisting threshold is reached. This suspension of the listing was intended to give all Generix Group shareholders and the market at large the opportunity to learn about this project.

About Generix Group

Generix Group is a Collaborative Supply Chain expert present in 60 countries, thanks to its subsidiaries and network of partners. More than 6,000 companies around the world use its SaaS solutions. The group's 800 employees provide daily support for such customers as Carrefour, Danone, FM Logistic, Fnac-Darty, Essilor, and Ferrero in the digital transformation of their Supply Chain.

Its collaborative platform, **Generix Supply Chain Hub**, helps companies to keep the promises they make to their customers. It combines the capabilities to execute physical flows, digitalize information flows, manage collaborative processes and connect companies to all their partners, in real time.

Generix Supply Chain Hub is aimed at all players in the Supply Chain: manufacturers, third- and fourth-party logistics providers (3PL/4PL) and retailers.

Founded in France in 1990, the company is listed on the Eurolist market of Euronext Paris, compartment B (ISIN: FR0010501692). To learn more: www.generixgroup.com

Financial Communication contact:

Generix Group – François Théry – Chief Financial Officer – Tél. : +33 (0)1 77 45 42 80 – ftthey@generixgroup.com